The Latest Breaking News from HIV

The US Food and Drug Administration on Wednesday approved Gilead Sciences' twice-yearly injection to prevent HIV -- a move the company hailed as a major breakthrough in the fight against the sexually transmitted virus.

A twice-yearly drug called lenacapavir is now the longest-lasting type of PrEP

IN FOCUS: Without US funding as leverage, one of Uganda’s most prominent LGBT+ activists Steven Kabuye tells Rachel Schraer, there are few ways to push the country towards change

The story of the AIDS movement is one of regular people: students, bartenders, stay-at-home mothers, teachers, retired lawyers, immigrants, Catholic nuns, newly out gay men who had just arrived in New York, and many others. Some had lost friends or lovers. Some felt a moral calling. Some were just trying…

IN FULL

Lifeblood will no longer ask men if they had sex with men in the past three months

Many gay and bisexual men have been excluded from donating blood and plasma (the liquid portion of blood) for decades because of rules developed during the HIV crisis in the 1980s.

Lifeblood heralds ‘world-leading plasma pathway’ amid change to HIV-era restrictions

Procuring lifesaving drugs is a daunting challenge in many low- and middle-income countries. Essential treatments are often neither available nor affordable in these nations, even decades after the drugs entered the market.

Campaigners say the US government has been withholding funds for orphans and vulnerable children unlawfully – before a vote in Congress has backed Trump’s move

As regulator prepares to approve Lenacapavir in the US, campaigners are urging the manufacturer, Gilead, to make it ‘available and affordable for all who need it’